India's patent case victory rattles Big Pharma.
The Lancet (Impact Factor: 39.21). 04/2013; 381(9874):1263. DOI: 10.1016/S0140-6736(13)60826-0
- [Show abstract] [Hide abstract]
ABSTRACT: Sarcomas are a rare and diverse set of cancers that disproportionately affect young people. The best possible outcome depends on access to highly specialised, multidisciplinary care. Although advances have been made in therapeutic techniques, access to some treatments might be limited by cost implications. This Review proposes an evidence-based, consensus recommendation for optimum management of bone and soft-tissue sarcoma across the Asia-Pacific region, taking into account variation in health-care resources, stratified according to the Breast Health Global Initiative resource levels. A web-based survey of 89 clinicians involved in the care of patients with sarcoma from 18 Asia-Pacific countries generated the recommendations for diagnosis, staging, and management, including supportive and palliative care, and research.The Lancet Oncology 11/2013; 14(12):e562-70. DOI:10.1016/S1470-2045(13)70475-3 · 24.73 Impact Factor
- Leukemia & lymphoma 05/2014; DOI:10.3109/10428194.2014.922183 · 2.61 Impact Factor
- Leukemia & lymphoma 05/2014; 55(12). DOI:10.3109/10428194.2014.921299 · 2.61 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.